GlassScriptPhysician profile
Alexander Potashinsky
NPI 1588923502
$5,178.38
in general payments reported to CMS, 2019-2025
30 companies · $1,762 in 2025
The $1,762 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $142 · 2022: $277 · 2023: $808 · 2024: $1,583 · 2025: $1,762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,135 · Education: $18.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,135.06 |
| Education | $18.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,266.39 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $545.20 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $538.40 | 2023-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $373.45 | 2019-2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $330.12 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $275.51 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $257.73 | 2023-2025 | Dupixent |
| Genzyme Corporation | $236.07 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $222.44 | 2023-2025 | Voquezna |
| Celgene Corporation | $145.52 | 2022-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $132.51 | 2022 | |
| Pfizer INC. | $116.63 | 2020-2024 | |
| Intercept Pharmaceuticals, INC. | $102.52 | 2019-2024 | Ocaliva |
| Ardelyx, INC. | $94.21 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $92.93 | 2024-2025 | Omvoh |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $87.94 | 2024 | Sucraid |
| Celltrion USA INC. | $69.95 | 2024-2025 | Vegzelma, Zymfentra |
| Ironwood Pharmaceuticals, INC | $36.70 | 2019-2024 | |
| Cook Medical LLC | $35.38 | 2019 | |
| Nestle Healthcare Nutrition INC. | $34.86 | 2023 | |
| Evoke Pharma, INC. | $32.55 | 2024-2025 | |
| Allergan, INC. | $24.55 | 2019-2020 | |
| Vivus LLC | $23.53 | 2025 | Pancreaze |
| Novo Nordisk INC | $23.11 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $22.49 | 2023 | Rebyota |
| Braintree Laboratories, INC. | $16.86 | 2023 | Sutab |
| Redhill Biopharma INC. | $15.48 | 2023 | Talicia |
| Merck Sharp & Dohme LLC | $13.30 | 2019 | |
| Alfasigma USA, INC. | $12.05 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Potashinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.